Efficacy assessment of a novel endolysin PlyAZ3aT for the treatment of ceftriaxone-resistant pneumococcal meningitis in an infant rat model.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
13
01
2022
accepted:
29
03
2022
entrez:
26
4
2022
pubmed:
27
4
2022
medline:
29
4
2022
Statut:
epublish
Résumé
Treatment failure in pneumococcal meningitis due to antibiotic resistance is an increasing clinical challenge and alternatives to antibiotics warrant investigation. Phage-derived endolysins efficiently kill gram-positive bacteria including multi-drug resistant strains, making them attractive therapeutic candidates. The current study assessed the therapeutic potential of the novel endolysin PlyAZ3aT in an infant rat model of ceftriaxone-resistant pneumococcal meningitis. Efficacy of PlyAZ3aT was assessed in a randomized, blinded and controlled experimental study in infant Wistar rats. Meningitis was induced by intracisternal infection with 5 x 107 CFU/ml of a ceftriaxone-resistant clinical strain of S. pneumoniae, serotype 19A. Seventeen hours post infection (hpi), animals were randomized into 3 treatment groups and received either (i) placebo (phosphate buffered saline [PBS], n = 8), (ii) 50 mg/kg vancomycin (n = 10) or (iii) 400 mg/kg PlyAZ3aT (n = 8) via intraperitoneal injection. Treatments were repeated after 12 h. Survival at 42 hpi was the primary outcome; bacterial loads in cerebrospinal fluid (CSF) and blood were secondary outcomes. Additionally, pharmacokinetics of PlyAZ3aT in serum and CSF was assessed. PlyAZ3aT did not improve survival compared to PBS, while survival for vancomycin treated animals was 70% which is a significant improvement when compared to PBS or PlyAZ3aT (p<0.05 each). PlyAZ3aT was not able to control the infection, reflected by the inability to reduce bacterial loads in the CSF, whereas Vancomycin sterilized the CSF and within 25 h. Pharmacokinetic studies indicated that PlyAZ3aT did not cross the blood brain barrier (BBB). In support, PlyAZ3aT showed a peak concentration of 785 μg/ml in serum 2 h after intraperitoneal injection but could not be detected in CSF. In experimental pneumococcal meningitis, PlyAZ3aT failed to cure the infection due to an inability to reach the CSF. Optimization of the galenic formulation e.g. using liposomes might enable crossing of the BBB and improve treatment efficacy.
Sections du résumé
BACKGROUND
Treatment failure in pneumococcal meningitis due to antibiotic resistance is an increasing clinical challenge and alternatives to antibiotics warrant investigation. Phage-derived endolysins efficiently kill gram-positive bacteria including multi-drug resistant strains, making them attractive therapeutic candidates. The current study assessed the therapeutic potential of the novel endolysin PlyAZ3aT in an infant rat model of ceftriaxone-resistant pneumococcal meningitis.
METHODS
Efficacy of PlyAZ3aT was assessed in a randomized, blinded and controlled experimental study in infant Wistar rats. Meningitis was induced by intracisternal infection with 5 x 107 CFU/ml of a ceftriaxone-resistant clinical strain of S. pneumoniae, serotype 19A. Seventeen hours post infection (hpi), animals were randomized into 3 treatment groups and received either (i) placebo (phosphate buffered saline [PBS], n = 8), (ii) 50 mg/kg vancomycin (n = 10) or (iii) 400 mg/kg PlyAZ3aT (n = 8) via intraperitoneal injection. Treatments were repeated after 12 h. Survival at 42 hpi was the primary outcome; bacterial loads in cerebrospinal fluid (CSF) and blood were secondary outcomes. Additionally, pharmacokinetics of PlyAZ3aT in serum and CSF was assessed.
RESULTS
PlyAZ3aT did not improve survival compared to PBS, while survival for vancomycin treated animals was 70% which is a significant improvement when compared to PBS or PlyAZ3aT (p<0.05 each). PlyAZ3aT was not able to control the infection, reflected by the inability to reduce bacterial loads in the CSF, whereas Vancomycin sterilized the CSF and within 25 h. Pharmacokinetic studies indicated that PlyAZ3aT did not cross the blood brain barrier (BBB). In support, PlyAZ3aT showed a peak concentration of 785 μg/ml in serum 2 h after intraperitoneal injection but could not be detected in CSF.
CONCLUSION
In experimental pneumococcal meningitis, PlyAZ3aT failed to cure the infection due to an inability to reach the CSF. Optimization of the galenic formulation e.g. using liposomes might enable crossing of the BBB and improve treatment efficacy.
Identifiants
pubmed: 35472061
doi: 10.1371/journal.pone.0266928
pii: PONE-D-22-01149
pmc: PMC9041855
doi:
Substances chimiques
Anti-Bacterial Agents
0
Vancomycin
6Q205EH1VU
Ceftriaxone
75J73V1629
Endopeptidases
EC 3.4.-
endolysin
EC 3.4.99.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0266928Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Antimicrob Chemother. 2003 Dec;52(6):967-73
pubmed: 14613958
Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4107-12
pubmed: 11259652
J Neuroinflammation. 2020 Oct 7;17(1):293
pubmed: 33028339
PLoS Pathog. 2007 Mar;3(3):e28
pubmed: 17381239
Vaccine. 2014 Sep 8;32(40):5185-91
pubmed: 25077419
Case Rep Dermatol. 2017 May 22;9(2):19-25
pubmed: 28611631
BMC Microbiol. 2012 Mar 15;12:33
pubmed: 22416675
FEMS Microbiol Lett. 2015 Jul;362(13):fnv098
pubmed: 26085488
J Infect Dis. 2010 Jan 1;201(1):32-41
pubmed: 19947881
FEMS Microbiol Lett. 2008 Oct;287(1):22-33
pubmed: 18673393
Infect Immun. 2014 Apr;82(4):1710-8
pubmed: 24491581
J Mol Biol. 1990 Oct 5;215(3):403-10
pubmed: 2231712
Antimicrob Agents Chemother. 2014 Nov;58(11):6484-9
pubmed: 25136018
Antimicrob Agents Chemother. 2003 Jan;47(1):375-7
pubmed: 12499217
J Antimicrob Chemother. 2015;70(6):1763-73
pubmed: 25733585
J Infect Dis. 2008 Jun 1;197(11):1519-22
pubmed: 18471063
Antimicrob Agents Chemother. 2012 Aug;56(8):4289-95
pubmed: 22644021
J Infect Dis. 2007 Oct 15;196(8):1237-47
pubmed: 17955443
Pediatr Infect Dis J. 2013 Mar;32(3):203-7
pubmed: 23558320
Pediatr Int. 2021 Sep;63(9):1133-1135
pubmed: 34176189
PLoS One. 2013 May 28;8(5):e64671
pubmed: 23724076
Clin Infect Dis. 2015 Sep 1;61(5):767-75
pubmed: 25972022
J Neuroinflammation. 2019 Jul 27;16(1):156
pubmed: 31351490
Int J Food Microbiol. 2008 Dec 10;128(2):212-8
pubmed: 18809219
Antimicrob Agents Chemother. 2017 May 24;61(6):
pubmed: 28348152
Clin Microbiol Infect. 2010 May;16(5):402-10
pubmed: 20132251
J Neuroinflammation. 2018 Aug 21;15(1):233
pubmed: 30131074
Pediatrics. 2019 Sep;144(3):
pubmed: 31420369
J Infect Dis. 2012 Feb 1;205(3):401-11
pubmed: 22158567
FEMS Microbiol Lett. 2015 Jan;362(1):1-8
pubmed: 25790497
Nat Rev Dis Primers. 2016 Nov 03;2:16074
pubmed: 27808261
Infect Immun. 2003 Nov;71(11):6199-204
pubmed: 14573637
Infect Immun. 2000 Feb;68(2):615-20
pubmed: 10639424
Science. 2001 Dec 7;294(5549):2170-2
pubmed: 11739958
N Engl J Med. 2004 Oct 28;351(18):1849-59
pubmed: 15509818
Clin Infect Dis. 2016 May 1;62(9):1119-25
pubmed: 26908787
Antimicrob Agents Chemother. 2019 Jun 24;63(7):
pubmed: 31061158
J Allergy Clin Immunol. 2019 Sep;144(3):860-863
pubmed: 31145938
Lancet Infect Dis. 2015 Mar;15(3):301-9
pubmed: 25656600
Int J Antimicrob Agents. 2011 Dec;38(6):516-21
pubmed: 21982146
Acta Neuropathol. 2007 Dec;114(6):609-17
pubmed: 17938941
J Antimicrob Chemother. 2013 Sep;68(9):2111-7
pubmed: 23633685
Int J Syst Evol Microbiol. 2012 Dec;62(Pt 12):2941-2945
pubmed: 22357776
Antimicrob Agents Chemother. 2005 Nov;49(11):4789-92
pubmed: 16251333